



8/9/2024

Notice Regarding Offer of Refunds to 340B Covered Entities

GlaxoSmithKline (“GSK”) recently recalculated 340B Ceiling Prices for the NDCs referenced below for the time period of July 1, 2022 through September 30, 2022 (3Q2022). As a result of the recalculation, GSK has determined that (pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4)), a refund is or may be due to any 340B Covered Entity which purchased any of the below NDCs during the aforementioned time period.

The table below identifies the NDCs that are subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data that were submitted to the Centers for Medicare & Medicaid Services.

Time Period	Product	NDC-11
07/01/2022 – 09/30/2022	NUCALA SOLUTION INJECT AI 100MG/ML 1X1ML	00173-0892-01
07/01/2022 – 09/30/2022	NUCALA SOLUTION INJECT SS 100MG/ML 1X1ML	00173-0892-42

GSK intends to refund any amount equal to or in excess of \$100 (aggregate for all applicable NDCs) for the periods listed directly to the 340B Covered Entity of record. Separate correspondence including a check and details of the payment will be sent to the qualifying 340B Covered Entity.

For 340B Covered Entities who may be owed less than \$100 in aggregate or who have questions about the above-referenced recalculation for this period, GSK invites interested parties to contact it via email at GSK.340BRefunds@gsk.com, with a reference to the NDC and time period.

GSK has asked the Health Resources and Services Administration (HRSA) to post this Notice on the HRSA’s public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Price recalculations for all NDC’s identified above and to offer a refund to any of the 340B Covered Entities that may have purchased the above NDCs during the relevant time periods. Please direct any questions and/or requests for additional information to GSK at the following email address: GSK.340BRefunds@gsk.com.

Banking Partner Change

As we improve GSK’s service standards and optimize our finance processes, this communication is to confirm that effective July 29, 2024, GSK has changed our banking partner from Citibank to JP Morgan.

Following the transition, all payments made by GSK, including electronic and check payments (where applicable) will be processed through our new JP Morgan account.

GlaxoSmithKline LLC. Banking Information:

Beneficiary's Bank Name and Address – JPMorgan Chase Bank, New York, NY 10017

Thank you for your cooperation. Please use the contact details below for help if needed:

Email: nam.bankingproject@gsk.com